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3The physical advantage
In the history of radiation therapy
there are many examples of how
cure rates have been increased
through improvements in physical
dose distribution and the resulting
increase in feasible tumor dose.
These examples include brachyther-
apy in gynecological tumors, stereo-
tactic radiotherapy, and proton
therapy in intraocular tumors. In
deep-seated tumors, the change
from orthovoltage x-ray therapy to
high-energy electron accelerators
has yielded a significant improve-
ment in therapeutic results. In
many cases, however, an exact fit of
the irradiated volume to the target
volume is impossible due to the
physical characteristics of the gam-
ma rays or electron-bremsstrahlung
used in therapy: After a short build-
up, the dose progressively decreases
at greater depth. In a deep-seated
tumor, the integral dose is therefore
always lower than in the adjacent
healthy tissues.
Beams of charged particles (protons
or ions) produce a much more fa-
vorable dose distribution: For pro-
tons and ions, the delivered dose in-
creases at greater depth, and then
declines abruptly beyond a sharply
defined maximum known as the
Bragg peak. The location of this
maximum in the patient’s body can
be precisely determined by the en-
ergy of the particles. In addition,
protons and ions exhibit a small lat-
eral and range scattering, which is
another prerequisite for achieving a
tumor conform treatment. These
physical properties of charged-par-
ticle beams make it possible to sub-
stantially increase the tumor dose
while at the same time reducing the
integral dose in healthy tissues.
This increase in tumor dose is the
essential prerequisite for the im-
provement of curative success rates
The sparing of healthy tissues is es-
pecially relevant in radiotherapy of
children and adolescents, in whom
successful therapeutic results are
presently being achieved, and
whose long life expectancy man-
dates that the risk of late sequelae
and radiation-induced tumors be
minimized. 
Differences in physical dose dis-
tribution between protons and ion
beams (helium, carbon, oxygen, ne-
on and argon) result from two ef-
fects having opposite consequences:
As the atomic number increases,
both lateral scattering and range
dispersion decrease, resulting in a
more precise dose distribution. At
the same time, however, the quanti-
ty of nuclear reactions in the tissue,
in which mainly light fragments
with a somewhat longer range are
created, increases. As a result, the
steep dose drop-off at the end of the
range becomes unsharp. An opti-
mum in overall dose distribution
occurs between helium and oxygen. 
Advantages of Therapy
Using Protons and Ions 
Comparison of
treatment plan-
nings for photons
with four treatment
fields (top) and for
ions with two treat-
ment fields (bot-
tom). The target
area lies within the
red outline. With
ion irradiation, the
dose distribution
can be matched
much more accu-
rately to the tumor
volume. 
4The biological advantage
In addition to the favorable physical
dose distribution, a specific high-
LET effect (as is also encountered
with neutrons) becomes effective in
the case of ions as distinct from
protons: As the atomic number in-
creases, the linear energy transfer
(LET) in the cell increases sharply.
In areas of especially high energy
transfer, the biologically effective
mechanisms are thereby changed.
This manifests itself by an increase
of the relative biological effective-
ness (RBE) that in turn allows high-
er curative success rates for well
defined indications. Amongst these
indications are hypoxic tumors,
slowly growing tumors, and tumors
being less or almost non-responsive
to conventional photon therapy. 
With lighter ions such as carbon or
oxygen, this high-LET effect occurs
mainly in the Bragg peak, while the
repair capacity of cells in the entry
zone—the so-called plateau—re-
mains nearly unchanged, i.e. as is
the case with low-LET irradiation
(x-rays, gamma rays, electrons, pro-
tons). 
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deposition at the
end of the particle
track and the in-
creased biological
effectiveness ren-
der ions an out-
standing tool for
irradiating deep-
seated tumors. 
Biologically effec-
tive doses for pho-
tons, protons and
carbon ions. The
increased energy
Compared to conventional radia-
tion, protons and ions deposit a
higher physical dose at the end
of their range, i.e. within the
tumor volume. In addition, ions
exhibit an increased biological
effectiveness. The advantage of
protons compared to convention-
al radiation therapy has already
been clinically proven for specific
types of tumors. For selected in-
dications, an additional increase
in cure rates resulting from the
high-LET effect is beeing expect-
ed, and has in part been clinical-
ly substantiated. These and other
indications for the use of high-
LET particle beams need to be
evaluated in systematic clinical
studies. 
5History and international
development
The use of protons and ions in ra-
diation therapy of cancer patients is
an approach that has been pursued
since the mid-1950s. The pioneers
in radiation therapy with protons
and ions include the Lawrence Ber-
keley National Laboratory in Berke-
ley (protons, 1954, helium ions,
1957, carbon and heavier ions,
1975), the Harvard Cyclotron Labo-
ratory (HCL) in Boston (protons,
1961), and the Institute of Theoreti-
cal and Experimental Physics (ITEP)
in Moscow (protons, 1969). The
clinical studies were initially con-
ducted exclusively at research insti-
tutes for nuclear and particle phys-
ics, due to the availability there of
suitable accelerator systems. In
many locations this is still true
today. In such facilities, logistical
problems are common, as the envi-
ronment is not primarily designed
for medical requirements. Further-
more, availability of the ion beam
for medical applications is not unre-
stricted, making it difficult to evalu-
ate various indications with statisti-
cally significant numbers of pa-
tients.
To-date, approximately 25,000 pa-
tients have been treated worldwide
with proton beams, and about 850
with ion beams. Particle therapy
has been used especially in patients
with inoperable tumors of the head
and neck, or with pelvic tumors. 
Harvard University in Boston plays
a leading role in proton therapy.
More than 7,500 patients have been
treated there with a high degree of
success using an old nuclear-physics
cyclotron. A new, dedicated therapy
facility is currently under construc-
tion in Boston.
At the Loma Linda University Med-
ical Center in California, the first
proton therapy system directly inte-
grated into a hospital setting has
been in use since 1990. This ar-
rangement has worked out exceed-
ingly well. At present, about 1000
patients per year are being treated
with protons at Loma Linda. Be-
cause of the highly successful clini-
cal results in both centers (for ex-
ample, in treating prostate carcino-
mas) three additional centers for
proton therapy are currently under
construction in the U.S.A.
From 1975 through 1992, a total of
433 patients have been treated with
ions—mainly neon—at LBL in Ber-
keley. Despite the non-perfect radia-
tion treatment techniques, available
at that time the clinical results were
very promising. For specific indica-
tions, the tumor control rate was
improved by a factor of two or even
three, compared to conventional
therapy. In 1994, the National Insti-
tute for Radiological Sciences (NIRS)
in Chiba, Japan, started treating pa-
tients at the first dedicated facility
for ion therapy. Here too, the con-
cept of integrating the treatment
unit and the hospital under one roof
has been applied. To-date, some
400 patients have been treated with
carbon ions. The resulting data con-
cerning local tumor control (after 12
months) were so convincing that the
construction of a second ion therapy
facility has now been started in
Hyogo. In addition, three proton
facilities are in operation or being
planned in Japan. A total of five
particle therapy centres each will be
in operation in the U.S.A. and Ja-
pan within a few years. 
In Europe, a number of studies and
activities concerning particle thera-
py of deep-seated tumors have been
undertaken since the early 1990s.
Since 1996, a modern proton ma-
chine has been in operation at the
Paul Scherrer Institute in Villigen,
Switzerland. And since late in 1997,
the ion-beam therapy unit has been
in operation at GSI in the context of
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The cure rates of
patients with tu-
mors of the base of
the skull are higher
following irradia-
lied to the tumor.
This has been de-
monstrated by clin-
ical studies in the
U.S.A. and Japan. 
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dose can be app-
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a pilot project for the presently pro-
posed clinical facility. In addition to
the new project proposed here—the
construction of a clinical therapy
facility in Germany—two other pro-
ject proposals are currently under-
way in Europe: the TERA project in
Italy and the MED-AUSTRON pro-
ject in Austria. All European activi-
ties in particle therapy are being
coordinated within PIMMS (Particle
Ion Medical Machine Study) Study
Group at CERN. 
Overview of exist-
ing therapy facili-
ties for treating
deep-seated tumors
with protons and
ions. Worldwide
there are more
than 10 therapy
systems for protons
but only two facili-
ties for ions. Only
the U.S.A. and
Japan have dedi-
cated facilities
integrated into hos-
pital settings.
Based on the good
results of radiation
therapy with pro-
tons and ions,
additional facilities
are scheduled to
start operating this
year in both coun-
tries. As yet there
are no dedicated
clinical facilities
for particle therapy
in Germany and
Europe. 
The results to-date of cancer
treatment with protons and ions
prove without doubt the superior-
ity of particle therapy to conven-
tional methods for specific indi-
cations. As a result of its high
precision and the specific high-
LET effect, radiation therapy
with ions is recognized as the
treatment of choice for slow-
growing, inoperable, radiation-
resistant tumors (e.g., chordomas
and chondrosarcomas), especial-
ly in the vicinity of high-risk
organs like the brain stem, optic
nerve or spinal chord. To provide
optimal treatment of these clini-
cal indications and also to evalu-
ate additional indications, Ger-
many urgently needs a dedicated
therapy facility for protons and
ions that is directly integrated
into a hospital setting.
7To lay the groundwork for a clinical
facility, a pilot project for tumor
therapy using ion beams has been
conducted since 1994 in the context
of a joint project of the Radiologi-
sche Universitätsklinik, Heidelberg,
the Gesellschaft für Schwerionen-
forschung, Darmstadt, and the
Deutsches Krebsforschungszentrum,
Heidelberg, in cooperation with the
Forschungszentrum Rossendorf.
During four years of construction, a
radiation therapy unit was installed
at the GSI heavy-ion synchrotron. In
December 1997, the first two pa-
tients were treated with ion beams
at this facitlity—the first such treat-
ments in Europe. 
Several innovations were imple-
mented during the course of this
project. These include the intensity-
controlled raster scan method for
tumor-conform dose delivery, the
use of positron emission tomogra-
phy (PET) for the direct monitoring
of the beam in the patient, and the
development of a treatment plan-
ning system adapted to the special
properties of particle beams. 
The intensity-controlled raster scan
method
Tumor-conform irradiation can be
achieved with protons and ion
beams by steering the charged-par-
ticle beam laterally by means of
magnetic fields, and by adjusting
the penetration depth through the
energy of the ions. The irradiation
method developed at GSI is unique
worldwide, and represents a key
technology for the optimal use of
proton and ion beams. In this meth-
od, the tumor volume is subdivided
into layers of equal depth. By vary-
ing the energy of the ions, the pene-
tration depth of the beam is adjust-
ed. The individual layers are scan-
ned line by line, similar to the im-
age on a TV screen. The lateral
deflection of the beam is achieved
by means of rapidly controllable di-
pole magnets. To control the inten-
sity, each line is subdivided into pix-
els. The beam remains in a given
pixel until the calculated target dose
has been reached. As a result, this
method of intensity-controlled ras-
ter scans allows a precise three-di-
mensional scanning of the target
volume defined by the physician.
This approach represents a signifi-
cant improvement over convention-
al treatment methods with photons,
as well as over passive beam appli-
cation techniques previously used in
proton and ion beam therapy.
Online therapy monitoring
A special feature of therapy using
ions is the possibility to check the
position of the delivered beam with-
in the patient’s body “online”—i.e.
directly during the treatment. To ex-
ploit this possibility, the technique
of positron emission tomography
(PET) was further developed at the
Forschungszentrum Rossendorf for
use in ion therapy. On its path
through the tissues, a small propor-
tion of the ion beam is converted
into positron-emitting isotopes. In
the case of carbon as a therapeutic
beam, mostly lighter carbon iso-
topes having practically the same
range are generated. The positrons
emitted by these isotopes have a
very short range of only a few mil-
limeters, and upon encountering an
electron they emit two characteristic
The Pilot Project at GSI
magnetic deflectors tumor
last layer E min first layer E max
ion beam
Developed and first
used in radiation
therapy at GSI, the
raster scan method
makes it possible
to irradiate tumors
of any shape, how-
ever complex,
while sparing the
surrounding nor-
mal tissues. 
8gamma quanta at an angle of 180°
with respect to each other. These
gamma rays are imaged by a spe-
cial PET camera, providing informa-
tion about the position of the deliv-
ered beam within the body. By re-
constructing the PET signals, the
activity distribution can be com-
pared with target values established
in the treatment plan, which further
enhances the safety of the patient.
Also this direct monitoring of the
therapeutic beam using PET is a
worldwide first in particle therapy. 
Patient positioning and safety 
In addition, the stereotactic meth-
ods developed at the DKFZ for pa-
tient positioning have been adapted
to meet the requirements of particle
irradiation. To achieve highly repro-
ducible positioning throughout the
entire course of therapy of twenty
treatment sessions, an individual
head mask with characteristic refer-
ence lines is fashioned for each pa-
tient. This mask is firmly mounted
to a patient couch which can be
rotated and translated in all three
coordinate directions. Once immobi-
lized by this system, the patient is
then positioned on the moveable
table into the treatment position as
defined by a stationary laser coor-
dinate system. The accuracy of posi-
tioning is verified by means of x-ray
images in two orthogonal projec-
tions. Only when the position is ex-
act to a millimeter the treatment
will start. 
The monitoring and control system
of the entire facility meets the high-
est safety standards. The position
and intensity of the beam, for exam-
ple, are measured 10,000 times per
second. In the event of a deviation
from the planned values, the radia-
tion treatment is terminated within
half a millisecond—a small fraction
of the fastest possible human
is positioned exact
to a millimeter by a
mask mounted to
the patient couch.
carbon ions in De-
cember 1997. Dur-
ing the treatment
the patient’s head
response time. All monitoring and
checking devices are redundant and
operated independently of each
other. Even during a total failure of
all beam transport and deflection
systems, the ion beam would never
strike the patient, but pass harm-
lessly above. 
Within the pilot
project at GSI, the
first patients were
irradiated with
The newly developed intensity-
controlled raster scan method
allows for proton and ion beams
a dose application with a previ-
ously unattainable degree of pre-
cision. This facility allows an
optimal utilization of the physical
and biological advantages of
heavy charged particles. For ion
beams, the use of PET provides
the additional opportunity of
monitoring the beam position
and dose distribution during the
treatment. The new radiothera-
peutic technique moreover in-
cludes very precise patient posi-
tioning systems as well as com-
prehensive control and monitor-
ing systems to guarantee the pa-
tient’s safety throughout the
entire treatment. 
9Successful start of clinical studies
In December, 1997, the first two pa-
tients with radiation-resistant tu-
mors in the brain stem region were
treated with four or five fractions of
carbon ion radiation respectively,
integrated into a course of conven-
tional photon therapy. These radia-
tion treatments were completed suc-
cessfully and demonstrated both the
applicability of the new irradiation
method and the precision and relia-
bility of the overall system. The clin-
ical results of both treatments are
exceedingly favorable and promis-
ing. Although only a portion of the
therapy was conducted with ion
beams, a surprisingly rapid tumor
regression was noted in both
patients. 
Since August, 1998, clinical studies
have been formally started in the
context of the overall project. To-
date, a total of twenty patients have
been treated with ion beams at GSI.
In the next five years, several hun-
dred patients with inoperable tu-
mors of the brain and at the base of
the skull are scheduled to be treated
with ion beams, to conduct clinical
studies with the new irradiation
method and to verify ion therapy as
the method of choice for specific
indications, over conventional radi-
ation therapy. In addition, the expe-
rience gained in the pilot project—
both with respect to apparatus and
the clinical aspects—is intended to
flow directly into the presently pro-
posed project of a dedicated therapy
system in a hospital setting. 
Example of the
course of disease in
a cancer patient
after carbon ion
therapy. It can be
seen that the tumor
diagnosed before
the treatment (left)
at the base of the
skull (histology:
chordoma) has
rapidly responded
following ion irra-
diation (right). 
The applicability of the newly
developed radiation therapy
method has been successfully
demonstrated by the clinical
studies started at GSI. The treat-
ment results to-date are impres-
sive. However, no more than 50 to
70 patients per year can be treat-
ed at the GSI facility. The pro-
posed therapy facility integrated
into a hospital setting represents
the logical extension of this work,
with the aim of creating a clini-
cal base in Germany for therapy
with particle beams. 
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From the very start, the pilot project
at GSI included a design study for a
dedicated therapy accelerator in-
tended to evolve into the present
project proposal for a clinical facili-
ty. The plan for this clinical machine
is detailed in a separate Technical
Proposal. The following is an over-
view of its basic design and essen-
tial specifications. 
The intent is to build a therapy fa-
cility capable of providing protons
as well as a variety of clinically
interesting ions (helium, carbon,
oxygen). This flexibility will allow
comparative clinical studies in the
field of particle therapy, i.e. of the
role of ions versus protons for well
defined indications. The facility is
intended to accommodate about
1,000 patients per year. 
The intent in the medical use of the
therapy facility is to focus on treat-
ing mainly those tumors where no
satisfactory treatment has been
available to-date. These especially
include inoperable tumors of the
base of the skull and of the brain,
soft-tissue sarcomas, and prostate
carcinomas. In addition, the intent
is to treat those conditions in which
the risk of late effects is very high,
for example in tumors among chil-
dren and adolescents. Such complex
therapeutic strategies, some of them
in the context of multimodal thera-
py regimens, absolutely mandate
the integration of the system into a
hospital environment. 
Thereby, the proposed therapy facil-
ity will be a first important step in
closing the gap existing in Germany
and Europe concerning the use of
particle beam therapy in patient
care. In addition, the attainable pa-
tient throughput permits the rapid
and efficient completion of statisti-
cally valid studies of potential addi-
tional indications. 
The planned therapy system will be
housed in a building covering an
area of 70 x 60 meters. The heart of
the facility is the therapy accelera-
tor, comprising a compact linear ac-
celerator as injector and a synchro-
tron for the acceleration to the de-
sired final energy, which is variable
from pulse to pulse. On the injector
side, state-of-the-art developments
are being exploited in the areas of
ion sources and accelerator struc-
tures (ECR ion sources and RFQ/IH
Linac). After acceleration to the syn-
chrotron injection energy of 7 MeV
per nucleon, the ions pass through
a stripper foil where the entire elec-
tron shell is stripped off. In the syn-
chrotron—which has a diameter of
about 18 m and a magnetic rigidity
of B. = 1.0 to 6.6 Tm—the particles
are accelerated to the desired thera-
peutic energy, from 50 to 430 MeV
per nucleon. This corresponds to a
penetration depth of the particle
beams from 2 to 30 cm. 
The synchrotron feeds into a beam
transport system which guides the
ion beam into three different treat-
ment rooms. One room provides a
horizontal beam, the two others will
be equipped with a gantry system
allowing rotation of the therapeutic
beam about the patient. The gantry
systems allow further optimization
of treatment planning, especially for
patients with tumors in the trunk.
Their construction is a new area of
technology. Special challenges are
The Clinical System
synchrotron
LINAC
gantry gantry
horizontal beam
0 10 20 m
with a horizontal
beam pipe. 
Plan of the pro-
posed clinical ion
beam facility,
which comprises a
synchrotron feed-
ing three treatment
rooms, two with a
gantry and a third
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posed by the integration of the
raster scan method—which is indis-
pensable for a precise dose applica-
tion—within the gantry, and by the
adaptation of the PET method of
beam monitoring to a rotational
beam transport system. With the
exception of the gantry system, for
which in the meantime a complete
design has been developed at GSI,
the know-how for all other systems
already exists among the project
partners or has been developed in
the context of the pilot project. This
applies in particular to the raster
scan method, PET beam monitoring
and patient positioning as well as to
safety and monitoring systems. 
Implementation and schedule
The technical specifications are
summarized in a separate Technical
Proposal. The implementation and
commissioning will be undertaken
in cooperation with competent in-
dustrial partners. A site in the im-
mediate vicinity of the Radiologi-
sche Universitätsklinik and the
DKFZ has been proposed for the
location of the clinical facility. 
Project management will be the re-
sponsibility of the Radiologische
Universitätsklinik, Heidelberg,
which will also coordinate the im-
plementation of the construction. 
The DKFZ will be responsible for
treatment planning, dosimetry, pa-
tient positioning, and patient safety.
GSI has developed a complete de-
sign for the therapy facility, com-
prising the accelerator, beam trans-
port and attached gantry systems,
and will be responsible for its im-
plementation in cooperation with
industrial partners. 
The Forschungszentrum Rossendorf
will be in charge of adapting the
PET system used for beam monitor-
ing to the requirements of the gan-
try system. 
Five years must be allowed for the
construction of the system up to the
first patient treatment. This period
contains a one-year planning and
development phase, a three-year
construction phase, and a one-year
commissioning phase including all
safety checks and required
approvals. Assuming a start of the
development work in 1999, Ger-
many’s and Europe’s first clinical
facility for particle therapy could
begin treating patients in 2004. 
Costs and financing
The construction of the clinical facil-
ity will require DM 110 million in
funds for capital expenditures.
About DM 77 million of this will be
needed for the accelerator complex
including beam transport system
Technical specifi-
cations of the pro-
posed therapy
facility
and treatment rooms, and DM 33
million for the building including
furnishings. 
The proposed system design allows
the acceleration of protons as well
as ions. Because of their high preci-
sion and increased biological effec-
tiveness, however, ions are of spe-
cial therapeutic importance. Com-
pared to a machine for protons
only, the ion option calls for a more
costly configuration of the accelera-
tor system and the downstream
beam transport system. In the pro-
posed system, these requirements
amount to additional costs of about
25 percent in terms of capital in-
vestments. In the subsequent oper-
ating costs, which will decisively
influence per-patient treatment
costs, the difference amounts to 10
percent to 15 percent. Thus, a large
gain in therapeutic and scientific
possibilities from a configuration for
particles
accelerator type
beam energy
beam intensity (ions
per synchrotron pulse)
treatment rooms
beam application
method
gantry
online PET control
patient number per year
protons, 4He2+, 12C6+, 16O8+
synchrotron
protons : 4 x 1010
helium (4He2+) : 1 x 1010
carbon (12C6+) : 1 x 109
oxygen (16O8+) : 5 x 108
two rooms with gantry systems;
one room with firmly installed 
horizontal beam transport system
active energy and intensity variation from 
the accelerator plus rasterscan process 
isocentric geometry, barrel-type gantry, can 
be rotated 360°, with integrated rasterscan 
in front of the last deflection magnet
yes
1000
50 - 430 MeV per nucleon 
both proton and ion therapy, is
achieved for a low additional cost. 
The financing of the facility will be
obtained largely through bank cred-
its that will be paid back from sub-
sequent patient revenues. To get the
project started, an application has
been submitted to the Strategie-
fonds of the Helmholtz-Gemein-
schaft deutscher Forschungszentren
(HGF) for DM 10 million for capital
expenditures, and for 15 scientific
and engineering positions. These
funds will allow important R&D
work for the new project to go for-
ward. The focus of this work will be
on the development and clinical im-
plementation of multifield ion ther-
apy, comprising a gantry system
with integrated raster scan and
PET, as well as the associated, bio-
logically optimized treatment plan-
ning. 
The treatment cost per patient
should be set so as to cover the per-
sonnel costs for about 75 positions
to be newly created plus all operat-
ing costs including payback of the
credits obtained for the financing.
Given a capacity of 1,000 patients
per year, this amounts to an aver-
age treatment cost per patient of
about DM 40,000. This is compara-
ble to the costs entailed by major
surgical or pharmaceutical treat-
ment methods. The figure is far
lower than the amounts reimbursed
by health insurance companies for
costs arising from referral of cancer
patients to radiation clinics in the
U.S.A. or Japan. Consequently, the
project not only closes a healthcare
gap; given the relatively moderate
treatment costs and especially in
view of the attainable increase in
cure rates for a group of conven-
tionally untreatable patients, the
project contributes to a reduction
rather than a further increase in
healthcare costs. 
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The object of the new project is
the construction of a clinical ion
beam therapy system that will be
an international technological
trendsetter. This facility will
close a medical care gap in Ger-
many for established indications
and will also allow the evalua-
tion of new indications in large-
scale clinical studies. The clinical
therapy facility can be construct-
ed in five years by the participat-
ing institutions in cooperation
with industry. The required funds
for capital expenditures in the
amount of DM 110 million can be
refinanced through the subse-
quent patient revenues. To oper-
ate the facility at a break-even
level, average treatment costs
are set at DM 40,000 per patient. 
and has a radius of
nearly 6 meters
and a total weight
of 160 metric tons. 
tion system about
the patient. This is
particularly impor-
tant in tumors of
the trunk. The
gantry system can
be rotated 360°
about the patient,
The new project
also includes the
development and
implementation of
a gantry system for
ion beams that
allows rotation of
the beam applica-
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The implementation of the project
will be managed by the Radiologi-
sche Universitätsklinik through the
participating institutes in close co-
operation with industrial partners. 
The Radiologische Universitäts-
klinik, Heidelberg, Department of
Clinical Radiology (Schwerpunkt:
radiation therapy), is one of Ger-
many’s largest radiation therapy
centers, with about 2,800 new pa-
tients per year. In addition to pa-
tient care, a broad research pro-
gram in the area of radiation oncol-
ogy is pursued at Heidelberg. The
clinical studies of ion beam therapy
in the context of the pilot project
are also being conducted under its
management. 
The Deutsche Krebsforschungszen-
trum in Heidelberg, with a focused
program on radiological diagnostics
and therapy, is the center of inter-
nationally renowned research and
development in the field of leading-
edge techniques in radiation thera-
py. Here, major scientific achieve-
ments have been made in the field
of three-dimensional treatment
planning and precision radiothera-
py, including dosimetry and quality
assurance. The new therapeutic
methods are developed and clinical-
ly tested in the Clinical Cooperative
Unit for Radiotherapeutic Oncology,
in conjunction with the Radiologi-
sche Universitätsklinik. 
The Gesellschaft für Schwerionen-
forschung in Darmstadt is among
the internationally leading centers
of heavy-ion research. More than
1000 scientists from over 30 coun-
tries currently conduct research at
its accelerator facility. Since its
establishment, GSI has also been
conducting studies in radiation biol-
ogy, especially concerning the radio-
biologic effects of ions. In addition,
there is abundant expertise in the
areas of accelerator technology and
the development of highly precise
irradiation methods. With the SIS
heavy-ion synchrotron, GSI current-
ly has at its disposal the only accel-
erator system in Europe where pa-
tients with deep-seated tumors can
be treated with ions. 
The Forschungszentrum Rossendorf
near Dresden conducts basic and
applied research in the fields of ma-
terials research, biomedicine and
biochemistry, environmental re-
search, as well as nuclear, hadron
and radiation physics. The planned
clinical facility will especially benefit
from this institute’s in-depth exper-
tise in the biomedical application of
positron emission tomography
(PET). 
The Project Partners
Within of the pilot project, the
project partners have developed
new, trendsetting methods that
represent key technologies for
the proposed therapy system as
well as future projects. This
groundwork—in combination
with the expertise of the partici-
pating institutes in various areas
of particle therapy—represents
an ideal basis for a successful
completion of the new project,
jointly with industrial partners.
In view of the European and
international demand level for
such therapy systems, the project
represents a substantial business
opportunity for industry.
